Amgen experienced notable downward pressure due to a significant setback in the cardiovascular drug pipeline landscape. Competitor Novartis revealed that its Phase III trial for pelacarsen, an experimental therapy targeting elevated lipoprotein(a), failed to reduce major adverse cardiovascular events despite successfully lowering target lipid levels. This unexpected result rattled market sentiment across the entire lipoprotein(a)-lowering therapeutic class. Because Amgen is actively developing a key late-stage contender, olpasiran, in its own pivotal cardiovascular outcomes study, investors quickly reassessed the probability of success and future commercial viability for…